Go Deep
Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 27,683 | 0.6 | 0.63 | 0.00 | 120.58 |
| Oct 2026 | 27,702 | 0.6 | 0.62 | 0.00 | 118.70 |
| Oct 2026 | 27,731 | 0.6 | 0.61 | 0.00 | 115.55 |
| Oct 2026 | 27,741 | 0.6 | 0.60 | 0.00 | 114.73 |
| Oct 2026 | 27,798 | 0.5 | 0.57 | 0.00 | 109.04 |
| Oct 2026 | 27,779 | 0.5 | 0.58 | 0.00 | 110.66 |
| Oct 2026 | 27,827 | 0.5 | 0.56 | 0.00 | 105.72 |
Dogwood Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -11,529,609.0 | -4,986,614.0 | -3,780,449.0 | -15,744,616.0 |
| EPS | -0.3 | -0.1 | -0.3 | -8.2 |
Dogwood Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -34,257,370.0 | -12,349,724.0 | -5,296,015.0 | -12,247,834.0 | — |
| EPS | -7.1 | -12.5 | -7.0 | -27.8 | — |
Dogwood Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 90,171,237.0 | 94,308,246.0 | 4,165,442.0 | 8,369,756.0 |
| Total Liabilities | 15,274,370.0 | 30,027,223.0 | 358,548.0 | 1,043,262.0 |
| Total Equity | 74,896,867.0 | 64,281,023.0 | 3,806,894.0 | 7,326,494.0 |
Owes vs Owns
Dogwood Therapeutics, Inc. owed $0.15 for every $1 it owned in Jun 2026, up from $0.12 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.15× | 0.17× | 0.32× | 0.09× | 0.12× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Dogwood Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 7.2%Intangible assets 90.3%Other assets 2.3%
How it's funded — Dec 2025
Payables 0.8%Other liabilities 15.9%Shareholders' equity 83.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6.5 | 14.8 | 3.3 | 7.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.2 | 0.2 | 0.0 | 0.0 |
| Intangible assets | 81.4 | 77.5 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.1 | 1.7 | 0.8 | 1.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.1 | 15.4 | 0.0 | 0.0 |
| Payables | 0.8 | 1.2 | 0.1 | 0.6 |
| Other liabilities | 14.4 | 13.4 | 0.2 | 0.5 |
| Shareholders' equity | 74.9 | 64.3 | 3.8 | 7.3 |
| Net tangible assets | -6.5 | -13.2 | 3.8 | 7.3 |
Dogwood Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -15,618,651.0 | -8,790,805.0 | -4,870,489.0 | -11,467,797.0 | — |
| Investing Activities | 0.0 | 3,761,936.0 | 0.0 | — | — |
| Financing Activities | 7,284,806.0 | 16,704,464.0 | 1,156,443.0 | 4,490,605.0 | — |